These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1541 related items for PubMed ID: 18591625

  • 1. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F.
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [Abstract] [Full Text] [Related]

  • 2. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.
    Bigoni R, Cuneo A, Milani R, Cavazzini F, Bardi A, Roberti MG, Agostini P, della Porta M, Specchia G, Rigolin GM, Castoldi G.
    Haematologica; 2001 Apr; 86(4):375-81. PubMed ID: 11325642
    [Abstract] [Full Text] [Related]

  • 3. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR, Oh B, Hong DS, Zang DY, Yoon HJ, Kim HJ, Kim I, Ahn JS, Cheong JW, Lee KA, Cho KS, Lee MH, Bang SM, Kim TY, Yun YM, Min YH, Lee YK, Lee DS, AML/MDS Working Party of the Korean Society of Hematology.
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [Abstract] [Full Text] [Related]

  • 4. [Detection of -5/5q- chromosome abnormality in myelodysplastic syndromes by interphase fluorescence in situ hybridization].
    Shen Y, Xue Y, Li J.
    Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):517-9. PubMed ID: 11769675
    [Abstract] [Full Text] [Related]

  • 5. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
    Douet-Guilbert N, Herry A, LE Bris MJ, Guéganic N, Bovo C, Morel F, DE Braekeleer M.
    Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
    [Abstract] [Full Text] [Related]

  • 6. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
    Sun Y, Cook JR.
    Leuk Res; 2010 Mar; 34(3):340-3. PubMed ID: 19608274
    [Abstract] [Full Text] [Related]

  • 7. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
    Pitchford CW, Hettinga AC, Reichard KK.
    Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
    [Abstract] [Full Text] [Related]

  • 8. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A.
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [Abstract] [Full Text] [Related]

  • 9. Several chromosomes involved in translocations with chromosome 5 shown with fluorescence in situ hybridization in patients with malignant myeloid disorders.
    Bram S, Rödjer S, Swolin B.
    Cancer Genet Cytogenet; 2004 Nov; 155(1):74-8. PubMed ID: 15527906
    [Abstract] [Full Text] [Related]

  • 10. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.
    Beyer V, Castagné C, Mühlematter D, Parlier V, Gmür J, Hess U, Kovacsovics T, Meyer-Monard S, Tichelli A, Tobler A, Jacky E, Schanz U, Bargetzi M, Hagemeijer A, de Witte T, van Melle G, Jotterand M.
    Cancer Genet Cytogenet; 2004 Jul 01; 152(1):29-41. PubMed ID: 15193439
    [Abstract] [Full Text] [Related]

  • 11. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Giardini I, Rocca B, Zappatore R, Dambruoso I, Caresana M.
    Ann N Y Acad Sci; 2006 Nov 01; 1089():395-410. PubMed ID: 17261783
    [Abstract] [Full Text] [Related]

  • 12. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
    Evers C, Beier M, Poelitz A, Hildebrandt B, Servan K, Drechsler M, Germing U, Royer HD, Royer-Pokora B.
    Genes Chromosomes Cancer; 2007 Dec 01; 46(12):1119-28. PubMed ID: 17823930
    [Abstract] [Full Text] [Related]

  • 13. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China.
    Chen L, Li J, Zhu Y, Qiu H, Pan J, Wang R, Qian S, Xu W, Xue Y.
    Exp Oncol; 2007 Dec 01; 29(4):299-303. PubMed ID: 18199987
    [Abstract] [Full Text] [Related]

  • 14. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.
    MacKinnon RN, Kannourakis G, Wall M, Campbell LJ.
    Cancer Genet; 2011 Apr 01; 204(4):187-94. PubMed ID: 21536236
    [Abstract] [Full Text] [Related]

  • 15. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
    Lessard M, Hélias C, Struski S, Perrusson N, Uettwiller F, Mozziconacci MJ, Lafage-Pochitaloff M, Dastugue N, Terré C, Brizard F, Cornillet-Lefebvre P, Mugneret F, Barin C, Herry A, Luquet I, Desangles F, Michaux L, Verellen-Dumoulin C, Perrot C, Van den Akker J, Lespinasse J, Eclache V, Berger R, Groupe Francophone de Cytogénétique Hématologique.
    Cancer Genet Cytogenet; 2007 Jul 01; 176(1):1-21. PubMed ID: 17574959
    [Abstract] [Full Text] [Related]

  • 16. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
    Herry A, Douet-Guilbert N, Morel F, Le Bris MJ, De Braekeleer M.
    Eur J Haematol; 2007 Jun 01; 78(6):457-67. PubMed ID: 17391336
    [Abstract] [Full Text] [Related]

  • 17. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients.
    Yilmaz Z, Sahin FI, Kizilkilic E, Karakus S, Boga C, Ozdogu H.
    Clin Exp Med; 2005 Jul 01; 5(2):55-9. PubMed ID: 16096854
    [Abstract] [Full Text] [Related]

  • 18. [Detection of common chromosome abnormalities in myelodysplastic syndrome with a panel fluorescence in situ hybridization].
    Shen Y, Xue Y, Li J, Pan J, Wu Y, Chen S.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr 01; 20(2):160-3. PubMed ID: 12673589
    [Abstract] [Full Text] [Related]

  • 19. Three rearrangements of chromosome 5 in a patient with myelodysplastic syndrome: an atypical deletion 5q, a complex intrachromosomal rearrangement of chromosome 5, and a paracentric inversion of chromosome 5.
    Douet-Guilbert N, Basinko A, Eveillard JR, Morel F, Le Bris MJ, Guéganic N, Bovo C, Herry A, Berthou C, De Braekeleer M.
    Cancer Genet Cytogenet; 2010 Dec 01; 203(2):303-8. PubMed ID: 21156249
    [Abstract] [Full Text] [Related]

  • 20. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance].
    Cai Y, Qin YW, Wang C, Yang J, Yan SK.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan 01; 28(1):6-10. PubMed ID: 17649717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.